TNFRSF10A Antibody

1. A graphene-based nanocarrier modified with death receptor 4 (DR4) antibody and AKT siRNA has been developed, which can synergistically strengthen death receptor-mediated apoptosis and enhance the cancer therapeutic effect in vivo. PMID:30430148
2. By downregulating TRAIL-R1, TGFbeta1 may not only promote tumor escape from immune surveillance but also negatively impact on TRAIL- or TRAIL-R1-based therapy regimens for treatment of Pancreatic ductal adenocarcinoma. PMID:27492861
3. findings together highlight a previously undiscovered mechanism that positively regulates DR4 expression through activation of the MEK/ERK/AP-1 signaling pathway. PMID:27576686
4. results suggest that the altered TRAIL, DR4 alleles and sTRAIL levels may be associated with some other potential biomarkers for vitiligo PMID:26404509
5. These statistical data suggest that Thr209Arg in exon 4 of the TRAIL-R1 gene may not represent a modifier of susceptibility to cancer. PMID:26315998
6. LOC389641 promotes pancreatic ductal adenocarcinoma progression and increases cell invasion by regulating E-cadherin with the possible involvement of TNFRSF10A. PMID:26708505
7. Results showed DR4 promotor methylation and low protein expression level in patients with lung squamous carcinoma which correlated with the prognosis of the disease. PMID:26238205
8. Genetic variation of TRAIL-R1 rs4242392 is linked with response to interferon-based therapy for hepatitis C virus infection, and genetic variation IFN-gamma rs2069707 is associated with natural clearance of hepatitis C virus infection. PMID:25798684
9. The rs13278062 polymorphism of the DR4 gene not only can confer an increased risk for crohn disease, but may also influence the location of the lesions and the disease behaviors. PMID:26418999
10. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. PMID:25605010
11. Our observations suggested that genetic variants of the DR4 gene significantly influence the risk of PCa in North Indian population and might be involved in the etiology of PCa. PMID:25691252
12. TRAIL-DR4 polymorphism is associated with laryngeal squamous cell carcinoma. PMID:25605161
13. was statistically significant association between DR4 expression in basal cell carcinoma and histopathologic subtypes PMID:24212133
14. Over-expression of TRAIL-R1 is associated with breast cancer. PMID:25230899
15. human TRAIL-R1 SNPs modulate the innate immune response against chlamydial infection. This is the first evidence that human TRAIL-R1 is a negative regulator of inflammation and plays a role in modulating Chlamydia pathogenesis. PMID:24695582
16. DR4 polymorphism C626G and A683 rather than A1322G are associated with cancer risk. PMID:24761920
17. DR4 haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population. PMID:24587306
18. Report DR4 up-regulation in alveolar epithelial cells from idiopathic pulmonary fibrosis patients. PMID:24551275
19. propose a model of TRAIL receptor interference driven by PLAD-mediated formation of receptor heterodimers on the cell membrane PMID:24764293
20. Investigated the association between G422A, C626G, A683C and A1322G polymorphisms in DR4 gene and lung cancer. PMID:23661154
21. C626G and A1322G polymorphisms of DR4 are associated with increased cancer risk, but the A683C polymorphism is rarely associated with cancer risk PMID:24492941
22. Malignant transformation in the endometrium is related to reduction of membrane DR4 and DR5 expression PMID:23815209
23. the gradual increase in TRAIL receptor expression during colorectal carcinogenesis is at least partially mediated through increased beta-catenin expression. PMID:24379239
24. lipid microdomains could exert a catalytic role for DR4-mediated cell death. PMID:24136227
25. SNP rs13278062, but not rs1713985 showed nominal evidence of association with AMD in a total of 1273 cases and 1652 controls of Chinese descent. PMID:24235014
26. The antiproliferative GSI-I/TRAIL synergism was stronger in ER-negative MDA-MB-231 breast cancer cells compared with ER-positive MCF-7 cells. In MDA-MB-231 cells, GSI-I treatment induced upregulation of DR4 and DR5 TRAIL receptors PMID:23686163
27. Deletion of TRAIL-R2) is relevant to the loss of 8p21.3 and plays a role in the pathogenesis of multiple myeloma. PMID:23423784
28. Loss of membrane TRAIL-R1 expression is associated with early stage colorectal cancer. PMID:23284732
29. endogenous MARCH-8 regulates the steady-state cell surface expression of TRAIL-R1. PMID:23300075
30. the C626G polymorphism of DR4 may be associated with the risk and severity of lumbar disc degeneration in the Chinese Han population PMID:23050498
31. Endometriosis is not associated with osteoprotegerin gene polymorphism. PMID:22392486
32. DR4 is forming DISC complex to activate proximal caspases for apoptosis by TRAIL. PMID:22240897
33. we found that the TRAIL receptor I wild type with threonine at amino acid position 209 (626C) and alanine at position 228 (638A) is associated with an increased risk of Hepatocellular carcinoma in patients with chronic hepatitis C. PMID:22401174
34. DR4, both as the complete form or as its new short isoform, is involved in TRAIL sensitivity in Ewing's sarcoma. PMID:22258765
35. A significant association of DR4 683A > C with a higher risk for ovarian cancer in carriers of BRCA1 mutations. PMID:21484799
36. The key differential events in apoptotic cells are p53-dependent activation of the DR4 death receptor pathway, caspase 8-mediated cleavage of BID, and BID-dependent activation of poised BAX at the mitochondria. PMID:22246181
37. miR-25 target DR4 provides a mechanism by which miR-25 contributes to evasion of TRAIL-induced cholangiocarcinoma apoptosis PMID:21953056
38. This pilot study suggests that loss of TRAIL receptors is a frequent feature of hepatocellular carcinoma and an independent predictor of survival in patients undergoing partial hepatectomy. PMID:20889918
39. ATRA upregulated TRAIL-R1 transcription in human cancer cells via 2 putative retinoic acid response elements: Pal-17 (a palindrome separated by 17 bases) & DR-11 (a direct repeat separated by 11 bases) in the 5'-flanking region. PMID:21685476
40. Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians. PMID:21700414
41. There was no chenage in expression of DR4 in leukemic cell lines after treatment with sodium butyrate. PMID:19379558
42. The rs4242392 SNP of the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 gene predicted poor interferon-based HCV treatment response in HIV/HCV-coinfected patients. PMID:20802294
43. Data show that the apoptosis mechanisms underlying this sensitization mainly involved diosgenin-induced p38 MAPK pathway activation and subsequent DR5 overexpression. PMID:21195543
44. TRAIL-R1 expression was an independent prognostic marker for better survival in all CRC samples and even in the CRC group that received adjuvant therapy PMID:20673328
45. TRAIL receptor DR4 was highly expressed in THP-1 & LPS-primed primary monocytes but not in the non-primed primary monocytes. TRAIL induces monocyte migration mediated by TRAIL receptor DR4 via the RhoGTPase signaling pathway. PMID:20638129
46. five tentative epitopes on human TRAIL-R1 were shown to be post-translationally modified on some tumor cell lines. PMID:20363213
47. Human DR4 is regulated by activator protein 1 via the AP-1-binding site at -350/-344. PMID:12082627
48. induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway PMID:12239152
49. Tyrosine-based sorting signal in adenovirus RID plays a role in RID's ability to down-regulate TRAIL R1 receptor and inhibit TRAIL induced apoptosis PMID:12388693
50. Decreased expression of DR4 may contribute to prolonged survival of eosinophils in the airways of allergic asthmatics following segmental antigen challenge. PMID:12421985

Show More

Hide All

HGNC: 11904

UNIGENE: Hs.213467

KEGG: hsa:8797

STRING: 9606.ENSP00000221132

OMIM: 603611